NCT02685033View on ClinicalTrials.gov

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

December 12, 2017

Study Completion Date

December 12, 2017

Conditions
Osteomyelitis
Interventions
DRUG

Dalbavancin

DRUG

Comparator

Trial Locations (1)

18009

Allergan Investigative Site 001, Cherkasy

All Listed Sponsors
lead

Durata Therapeutics Inc., an affiliate of Allergan plc

INDUSTRY

NCT02685033 - Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis | Biotech Hunter | Biotech Hunter